Cao Fei made an offer to acquire 38.2% stake in Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) for CNY 8.7 billion on June 13, 2025. In this transaction, Cao Fei has offered the acquisition of 350.8 million shares in Hubei Jumpcan Pharmaceutical at CNY 26.93 per share. Due to the implementation of the equity distribution, the tender offer price was adjusted from CNY 26.93/ share to CNY 24.85/ share.

The tender offer period is 30 natural days, i.e. June 18, 2025, to July 17, 2025.

Beijing Bestar Consultant Co., Ltd. acted as financial advisor and Beijing Merits & Tree Law Offices acted as legal advisor to Cao Fei.

Cao Fei completed the acquisition of 0.0018% stake in Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) for CNY 0.41 million on July 17, 2025. Cao Fei holds 16,300 shares directly in Hubei Jumpcan Pharmaceutical.